Annovis Bio (ANVS) Operating Expenses (2019 - 2026)
Annovis Bio (ANVS) posted Operating Expenses of $18.0 million for Q1 2026, up 85.57% sequentially from $9.7 million in Q4 2025, and up 186.7% YoY from $6.3 million in Q1 2025.
Annovis Bio (ANVS) Operating Expenses (2019 - 2026) Analysis & Trends
Annovis Bio has reported Operating Expenses for 8 years, with the latest figure at $18.0 million in Q1 2026.
- Quarterly Operating Expenses rose 186.7% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.4 million (up 64.59% YoY) and the FY2025 annual result came in at $29.7 million, up 11.24% from the prior year.
- Operating Expenses grew to $18.0 million in Q1 2026 per ANVS's latest filing, from $9.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $18.0 million in Q1 2026 and troughed at $4.4 million in Q3 2024.
- A 5-year average of $8.5 million and a median of $7.8 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2026: Operating Expenses sank 70.48% in 2024, then surged 186.7% in 2026.
- Over 5 years, Operating Expenses stood at $7.8 million in 2022, then surged by 33.87% to $10.4 million in 2023, then tumbled by 35.5% to $6.7 million in 2024, then soared by 44.12% to $9.7 million in 2025, then soared by 85.57% to $18.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $18.0 million, $9.7 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 14.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.01 Mn |
| Dec 31, 2025 | 9.71 Mn |
| Sep 30, 2025 | 7.43 Mn |
| Jun 30, 2025 | 6.27 Mn |
| Mar 31, 2025 | 6.28 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 7.76 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 10.44 Mn |
| Sep 30, 2023 | 14.86 Mn |
| Jun 30, 2023 | 9.76 Mn |
| Mar 31, 2023 | 9.97 Mn |
| Dec 31, 2022 | 7.80 Mn |
| Sep 30, 2022 | 6.48 Mn |
| Jun 30, 2022 | 5.97 Mn |
| Mar 31, 2022 | 5.25 Mn |
| Dec 31, 2021 | 5.92 Mn |
| Sep 30, 2021 | 2.85 Mn |
| Jun 30, 2021 | 2.53 Mn |